PepKon

Develops first-in-class peptides that have demonstrated preclinical efficacy in several solid and liquid cancers, notably chronic lymphocytic leukemia, with no observed toxicity. Thanks to an innovative platform combining biology, chemistry and artificial intelligence, peptides are designed to specifically target CD47, enabling tumour cells to be destroyed while sparing healthy cells.